Hemoglobin solutions
- 1 December 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 31 (Supplement) , S698-S707
- https://doi.org/10.1097/01.ccm.0000098037.40520.81
Abstract
To review current knowledge about cell-free hemoglobin solutions.A computerized MEDLINE search was used to retrieve all studies concerning cell-free hemoglobin solutions from 1990 to 2003. The reference lists of all available review articles and primary studies were also reviewed to identify references not identified in the computerized search.All clinical and experimental studies involving cell-free hemoglobin solutions were included.From the selected studies, information was obtained regarding the experimental model or the study population in which cell-free hemoglobin solutions were investigated, the type of cell-free hemoglobin solution used, their deleterious or beneficial effects, and their possible indications.In many studies, hemoglobin solutions were considered as efficient resuscitative agents and good alternatives to red blood cell transfusion, owing to their marked vasopressor effect, coupled with their capacity to improve the microcirculation and rapidly restore metabolic parameters. The main problems identified include excessive systemic vasoconstriction and oxidative damage. Initial enthusiasm in the development of hemoglobin solutions has been tempered recently by the negative results of a U.S. multicenter trial studying the early infusion of diaspirin cross-linked hemoglobin in trauma patients. Nevertheless, the properties of diaspirin cross-linked hemoglobin (and particularly the strong vasopressor effects) cannot be attributed to all hemoglobin solutions, and results of new clinical studies are eagerly awaited to evaluate the potential benefit of such solutions in the management of trauma patients.Today, we are aware of the effects of the first generation of blood substitutes. Further research is ongoing into newer solutions. One area of interest is the development of new molecular structures to decrease nitric oxide binding, thus minimizing any adverse events and maximizing potential benefits. Nevertheless, possible adverse effects need to be carefully evaluated before these agents can be widely administered.Keywords
This publication has 96 references indexed in Scilit:
- BENEFICIAL VERSUS DETRIMENTAL EFFECTS OF NITRIC OXIDE SYNTHASE INHIBITORS IN CIRCULATORY SHOCK LESSONS LEARNED FROM EXPERIMENTAL AND CLINICAL STUDIESShock, 1997
- Diffusion coefficients of oxygen and hemoglobin measured by facilitated oxygen diffusion through hemoglobin solutionsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1997
- Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat.Journal of Clinical Investigation, 1997
- Effects of a Novel Hemoglobin-Based Oxygen Carrier on Percent Oxygen Saturation as Determined With Arterial Blood Gas Analysis and Pulse OximetryAnnals of Emergency Medicine, 1996
- Diaspirin cross-linked hemoglobin improves neurological outcome following reversible but not irreversible CNS ischemia in rabbits.Stroke, 1994
- Hemodilution with Oxyhemoglobin Mechanism of Oxygen Delivery and Its Superaugmentation with a Nitric Oxide Donor (Sodium Nitroprusside)Anesthesiology, 1993
- Focal Cerebral Ischemia in RatsAnesthesiology, 1993
- Heart Protection by Cardioplegic Solutions Containing Oxyhemoglobin Pretreated by Carbontetrachloride and Freeze-Drying with SucroseBiomaterials, Artificial Cells and Immobilization Biotechnology, 1992
- Does Oxygen Supply Improve Graft Viability in Liver Preservation?Biomaterials, Artificial Cells and Immobilization Biotechnology, 1992
- The effect of hemodilution with stroma-free hemoglobin and dextran on collateral perfusion of ischemic myocardium in the dogAmerican Heart Journal, 1980